Apixaban to prevent blood clots in people with lung cancer
Tests whether the tablet apixaban prevents blood clots in people having lung cancer treatment.
Key facts
- Who runs it
- University of Birmingham
- Where
- Dorchester, Exeter, Gorleston-on-Sea, Haverfordwest, London, Romford, Shrewsbury, and Sutton in Ashfield, United KingdomSee the 8 sites
- Trial code
- Registry title
- Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 1,456 people, planned
- Started
- 28 Apr 2026
- Expected to end
- 30 Mar 2030
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Apixaban
- Placebo
- Record updated
- 28 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults and teenagers with lung cancer who are starting a new course of cancer drug treatment as outpatients. It tests whether apixaban tablets reduce blood clots.
- Age
- 16 years or older
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed locally advanced or metastatic primary lung cancer, or disease that progressed after complete or partial remission. The cancer must be confirmed by tissue or cell tests.
- Earlier treatment
- Must be starting a new course of systemic anticancer treatment (SACT), alone or with radiotherapy (CRT), as an outpatient. Cannot be on continuous anticoagulation for other medical conditions.
Main reasons for not taking part
- Active significant bleeding or a condition with a high risk of major bleeding
- Platelet count < 50 x 109 /L, liver disease with impaired function, or kidney failure (creatinine clearance < 15ml/min)
- Weight < 40kg (88 lb (40 kg)) or expected life expectancy < 6 months
- Pregnancy or breast feeding
- Cancer treatment given before or after surgery for lung cancer that can be removed
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Age ≥ 16 years
- Newly diagnosed locally advanced or metastatic primary lung cancer (histologically/ cytologically confirmed) or disease progression after complete or partial remission commencing a new course of SACT alone or as CRT
- Ambulatory (receiving outpatient SACT)
Who cannot take part
- The usage of medications contraindicated with apixaban
- Receiving SACT for potentially resectable / resectable lung cancer as part of neo-adjuvant or adjuvant treatment
- Hypersensitivity to apixaban or to any of the listed SmPC excipients
- Active clinically significant bleeding
- Lesion or condition considered a significant risk factor for major bleeding
- Hepatic disease associated with impaired synthetic function
- Continuous anticoagulation (e.g., unfractionated heparin, low molecular weight heparins, heparin derivatives and oral anticoagulants) for other medical conditions
- Platelet count < 50 x 109 /L
- Elevated liver enzymes ALT/AST > 2 x ULN or total bilirubin ≥ 1.5 x ULN
- Renal failure (creatinine clearance < 15ml/min)
- Weight < 40kg
- Estimated life expectancy < 6 months
- Pregnancy
- Breast feeding
- Judgement by the Investigator that the participant is unsuitable to participate in the trial and the participant is unlikely to comply with trial procedures, restrictions and requirements
- Inability to consent
- SACT with significant potential DDI with apixaban (section 7.2.3)
Where in United Kingdom
- Dorset County HospitalDorchester, United KingdomContact: Amelie Harle, DrTaking people
- Royal Devon and Exeter HospitalExeter, United KingdomContact: Elizabeth Toy, DrTaking people
- James Paget HospitalGorleston-on-Sea, United KingdomContact: May Han, DrTaking people
- Withybush General HospitalHaverfordwest, United KingdomContact: Alison Brewster, DrTaking people
- Queen Elizabeth HospitalLondon, United KingdomContact: Daniel Hughes, DrTaking people
- Queens Hospital RomfordRomford, United KingdomContact: Kathryn Tarver, DrTaking people
- Royal Shrewsbury HospitalShrewsbury, United KingdomContact: Anirban Chatterjee, DrTaking people
- Kings Mill HospitalSutton in Ashfield, United KingdomContact: Ananth Sivanandan, DrTaking people
About the trial
What the trial wants to find out
The aim of this trial is to find out if a tablet called apixaban can reduce blood clots in people with lung cancer having chemotherapy or similar treatments. Apixaban is a type of oral anticoagulant ("blood thinner") that makes the blood less sticky to prevent blood clots forming.
Read full original descriptionShow less
The trial is trying to find out if apixaban it can reduce blood clots in people with lung cancer.
Participants will receive the following treatment:
• Apixaban or placebo, 2.5mg taken by mouth twice a day for 6 months. This treatment will be taken in addition to any treatment that they are receiving to treat their lung cancer.
Participants will need to:
* Sign a consent form to enter the trial. * Take the trial treatment as directed by the research team * Complete a participant diary to record when they took the trial treatment * Complete the Quality of Life and Health resource use questionnaires. * Female participants of childbearing potential must use adequate contraception during the trial and for at least 2 days after trial treatment has finished.
The 2 groups in the trial
- ApixabanTreatment being tested
apixaban 2.5 mg twice a day for 6 months
- PlaceboPlacebo, for comparison
apixaban matched placebo twice a day for 6 months
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase III, Multicentre, Double Blind, Placebo-Controlled, Randomised Clinical Trial of Apixaban THROMBOprophylaxiS TO Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment
- Plain-language title
- Apixaban to prevent blood clots in people with lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 28 September 2026